RMD is seeing rising device demand, expanding international sales and strong liquidity, but macroeconomic pressures could ...
Earnings call ResMed reported Q1 FY26 revenue of $1.34B, up 9% YoY (8% in constant currency), driven by 8% device and 10% mask growth globally. Gross margin expanded 280bps YoY to 62%, and EPS rose 16 ...
Zacks Investment Research on MSN
Here's how much a $1000 investment in ResMed made 10 years ago would be worth today
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across ...
ResMed is rated a buy due to strong fundamentals, expanding margins, robust cash flow, and resilience in recessionary environments. RMD's steady topline growth, high profitability, low debt, and ...
Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0% Income from operations increased 15%; non-GAAP ...
SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced that its ...
The big unknown in the sleep apnea world continues to be when Philips will re-enter the market. ResMed has more than risen to the challenge of meeting unprecedented demand in the competitor's absence, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback